首页 | 本学科首页   官方微博 | 高级检索  
检索        

老年局限期SCLC放疗时机选择探讨
引用本文:王优优,许昆鹏,徐利明,王军,庞青松,袁智勇,赵路军,王平.老年局限期SCLC放疗时机选择探讨[J].中华放射肿瘤学杂志,2018,27(1):49-52.
作者姓名:王优优  许昆鹏  徐利明  王军  庞青松  袁智勇  赵路军  王平
作者单位:300060 天津医科大学肿瘤医院放疗科 国家肿瘤临床医学研究中心 天津市肿瘤防治重点实验室 天津市恶性肿瘤临床医学研究中心
基金项目:国家自然科学基金(81372429、30970864)
摘    要:目的 探讨老年局限期SCLC放化疗中放疗时机选择对预后影响。方法 回顾分析2008—2014年行根治性胸部序贯放化疗的80例老年局限期SCLC患者的临床资料,分析从治疗开始至放疗结束时间(SER)、诱导化疗周期数与OS及PFS的关系,进而比较早放疗组(诱导化疗周期数≤3个37例)与晚放疗组(诱导化疗周期数>3个43例)疗效的差别。采用Kaplan-Meier法进行生存分析。结果 全组中位OS、PFS分别为23.5、13.3个月;SER与OS、PFS差异有统计学意义(P=0.001、0.001);2、3、4、5、6周期诱导化疗后接受放疗病例的中位OS分别为33.2、26.7、20.6、16.9、17.9(P=0.000);中位OS及1、2、5年OS早放疗组分别为27.8个月及87%、62%、34%,晚放疗组分别为17.9个月、74%、37%、15%(P=0.017);中位PFS及1、2、5年PFS早放疗组分别为17.1个月及65%、43%、28%,晚放疗组分别为11.9个月及49%、21%、14%(P=0.022)。结论 老年局限期SCLC序贯放化疗患者SER越短疗效越好,早放疗可使生存获益。

关 键 词:肺肿瘤/诱导化疗  肺肿瘤/放射疗法  预后  
收稿时间:2017-05-16

Timing of radiotherapy for limited-stage small cell lung cancer in the elderly
Wang Youyou,Xu Kunpeng,Xu Liming,Wang Jun,Pang Qingsong,Yuan Zhiyong,Zhao Lujun,Wang Ping.Timing of radiotherapy for limited-stage small cell lung cancer in the elderly[J].Chinese Journal of Radiation Oncology,2018,27(1):49-52.
Authors:Wang Youyou  Xu Kunpeng  Xu Liming  Wang Jun  Pang Qingsong  Yuan Zhiyong  Zhao Lujun  Wang Ping
Institution:Department of Radiation Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tian Jin; Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,China
Abstract:Objective To investigate the effect of the timing of radiotherapy on the prognosis of limited-stage small cell lung cancer (LS-SCLC) in the elderly. Methods A retrospective analysis was performed on the clinical data of 80 elderly patients with LS-SCLC who were treated with radical sequential thoracic chemoradiotherapy from 2008 to 2014.The correlations of SER (time from the start of any treatment to the end of radiotherapy) and the number of induction chemotherapy cycles with overall survival (OS) and progression-free survival (PFS) rates was analyzed. The treatment outcomes were compared between early radiotherapy group (no later than 3 cycles of induction chemotherapy,n=37) and late radiotherapy group (after 3 cycles of induction chemotherapy,n=43).The Kaplan-Meier method was used for survival analysis. Results In all patients,the median OS and PFS were 23.5 and 13.3 months respectively. SER was significantly correlated with OS and PFS (P=0.001;P=0.001).The median OS in patients undergoing radiotherapy after 2,3,4,5,and 6 cycles of induction chemotherapy was 33.2,26.7,20.6,16.9,and 17.9 months (P=0.000),respectively. The median OS time and 1-,2-,and 5-year OS rates were 27.8 months,87%,62%,and 34%,respectively,in the early radiotherapy group,and 17.9 months,74%,37%,and 15%,respectively,in the late radiotherapy group (P=0.017).The median PFS time and 1-,2-,and 5-year PFS rates were 17.1 months,65%,43%,and 28%,respectively,in the early radiotherapy group,and 11.9months,49%,21%,and 14%,respectively,in the late radiotherapy group (P=0.022). Conclusions Shorter SER achieves better treatment outcomes in elderly patients with LS-SCLC undergoing sequential chemoradiotherapy. Early radiotherapy provides a survival benefit for patients.
Keywords:Lung neoplasms/radiotherapy  Lung neoplasms/chemotherapy  Prognosis  
点击此处可从《中华放射肿瘤学杂志》浏览原始摘要信息
点击此处可从《中华放射肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号